Research to elucidate the anti-tumor immune responses and develop the combination therapy in solid tumor

Research to elucidate the anti-tumor immune responses and develop the combination therapy in solid tumor - Research to elucidate the anti-tumor immune responses and develop the combination therapy in solid tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040280

Enrollment

100

Registered

2020-05-01

Start date

2018-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who doubted solid tumor in clinically or confirmed solid tumor histologically. 2) Patients who plan to give biopsy or surgery. 3) Patients who gave informed consent by oneself.

Exclusion criteria

Exclusion criteria: The cases an attending physician determined ineligible.

Design outcomes

Primary

Measure	Time frame
Analysis of tumor cells and immune cells in tumor microenvironment and peripheral blood.	—

Countries

Japan

Contacts

Public ContactYu Mizote

Osaka International Cancer Institute, Research center Department of Cancer Drug Discovery and Development

mizote-yu@oici.jp06-6945-1181

Outcome results